Surrozen Quote - SRZN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

9.94

Bid

3.98

Offer

13.00

Volume

6,972

9.43 Day's Range 10.48

4.50 52 Week Range 16.19

Market Cap

31.732M

Previous Close

10.56

Open

10.48

Last Trade

100

9.9213

Last Trade Time

Financial Volume

US$ 67,531

VWAP

9.6861

Average Volume (3m)

11,312

Shares Outstanding

3,198,786

Dividend Yield

PE Ratio

-0.74

Earnings Per Share (EPS)

-13.46

Revenue

Net Profit

-43.04M

Surrozen Inc is a class of therapeutics to treat serious diseases characterized by tissue injury. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS). Surrozen Inc is a class of therapeutics to treat serious diseases characterized by tissue injury. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS).

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.surrozen.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Surrozen Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SRZN. The last closing price for Surrozen was US$10.56. Over the last year, Surrozen shares have traded in a share price range of US$ 4.50 to US$ 16.19.

Surrozen currently has 3,198,786 shares in issue. The market capitalisation of Surrozen is US$31.73 million. Surrozen has a price to earnings ratio (PE ratio) of -0.74.

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are unique TPD technologies...

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models Treatment with SZN-043 in the Phase 1a trial was safe and well...

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN...

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the corneaSurrozen’s antibody...

Surrozen Provides First Quarter 2024 Financial Results and Business Update

SZN-043 Phase 1a clinical trial results to be presented at the 2024 European Association for the Study of the Liver (EASL) in Milan Preclinical data from ARVO 2024 demonstrate the promise of a...

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

In a preclinical model of pulmonary fibrosis, a Surrozen antibody-based SWAP platform molecule decreased pulmonary inflammation and fibrosis and improved lung function Surrozen Wnt mimetic SWAP...

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

-Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events-Phase 1a data demonstrated target engagement, a pharmacodynamic effect and effects on liver...

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

- $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of warrants- Initial capital funds expansion of Phase 1b trial in severe alcohol-associated...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.54	-5.15267175573	10.48	10.76	9.18	9769	9.7772015	CS
4	-1.2	-10.7719928187	11.14	11.99	9.18	6915	10.59917409	CS
12	-0.74	-6.92883895131	10.68	11.99	8.14	11312	10.380343	CS
26	1.41	16.52989449	8.53	16.19	7.15	14771	10.59510985	CS
52	0.595	6.3670411985	9.345	16.19	4.5	61474	8.49095211	CS
156	-133.31	-93.0610820244	143.25	210	4.5	171753	31.11920122	CS
260	-133.31	-93.0610820244	143.25	210	4.5	171753	31.11920122	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
IBGOIronbark Zinc Limited	AUD 0.002 (100.00%)	1M
CLZClassic Minerals Limited	AUD 0.0015 (50.00%)	3.56M
VMLVital Metals Limited	AUD 0.003 (50.00%)	400k
HVYHeavy Minerals Ltd	AUD 0.069 (30.19%)	217.11k
SIHSihayo Gold Limited	AUD 0.0025 (25.00%)	660.2k
MCTMetalicity Ltd	AUD 0.001 (-50.00%)	1.28M
BPHOBBPH Energy Limited	AUD 0.002 (-33.33%)	396.77k
OAROAR Resources Limited	AUD 0.001 (-33.33%)	300k
AVEAvecho Biotechnology Limited	AUD 0.002 (-33.33%)	200k
RIERiedel Resources Ltd	AUD 0.0015 (-25.00%)	120k
ADNAndromeda Metals Limited	AUD 0.016 (-11.11%)	17.11M
IMUImugene Limited	AUD 0.054 (0.00%)	14.27M
CXOCore Lithium Ltd	AUD 0.094 (-5.05%)	14.19M
SYASayona Mining Limited	AUD 0.036 (-2.70%)	13.85M
LSRLodestar Minerals Limited	AUD 0.001 (0.00%)	13.76M